ClinVar Miner

Submissions for variant NM_000546.5(TP53):c.992A>G (p.Gln331Arg) (rs1064795056)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000479182 SCV000570482 uncertain significance not provided 2016-05-31 criteria provided, single submitter clinical testing This variant is denoted TP53 c.992A>G at the cDNA level, p.Gln331Arg (Q331R) at the protein level, and results in the change of a Glutamine to an Arginine (CAG>CGG). This variant has not, to our knowledge, been published in the literature as either a pathogenic germline variant or a benign polymorphism. However, it has been reported as a somatic variant in large intestine carcinoma samples according to the Catalogue of Somatic Mutations in Cancer (COSMIC) database, as well as in prostate cancer cell lines (van Bokhoven 2003, Scott 2004, Cunningham 2015). This variant demonstrated transcriptional activation activity comparable to wild type (Kawaguchi 2005, Imagawa 2009, Leroy 2014) and retained its ability to form tetramers (Kamada 2011). Additionally, this variant is reported as having functional transactivation in the International Agency for Research on Cancer TP53 database based on functional assays by Kato et al. (2003). However, in a series of functional assays interrogating response to irradiation, Lehmann et al (2007a,b) found discrepant results, with formation of gamma-H2AX foci and cell survival comparable to wild-type, but impaired apoptotic activity and abnormal cell cycle progression, and ultimately defined this variant to have partial function. TP53 Gln331Arg was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Glutamine and Arginine differ in some properties, this is considered a semi-conservative amino acid substitution. TP53 Gln331Arg occurs at a position that is not conserved and is located within the tetramerization domain (Bode 2004). While protein-based in silico analyses are inconsistent regarding the effect this variant may have on protein structure and function, multiple splicing models predict that this variant may destroy the natural splice donor site for intron 9 and lead to abnormal splicing. However, in the absence of RNA studies, the actual effect of this variant is unknown. Based on currently conflicting evidence, it is unclear whether TP53 Gln331Arg is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.